Subscribe
Share
Share
Embed
Clinical trial data upgrades vitamin C into oncology territory, Galy debuts WunderHaus cell-cultured cocoa, FDA faces pressure on peptide loophole, and a German miller bets €7M on protein.
Vitamin C just earned clinical trial credibility in cancer survival — and Galy is bringing lab-grown cocoa to B2B ingredient buyers. Two stories reshaping formulation and marketing strategy today.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: Four strong stories lined up for you today.
Klara: Vitamin C is getting a serious scientific upgrade — new clinical trial data on cancer survival.
Marco: A German milling dynasty is dropping €7 million on protein ingredients, and it's a signal worth watching.
Klara: US lawmakers are coming for grey-market peptides — and Europe should be paying close attention.
Marco: Plus, cell-cultured cocoa just hit the B2B market. Let's get into it.
Marco: Vitamin C just got a serious scientific upgrade.
Marco: Most people think of vitamin C as the ingredient you reach for when you feel a cold coming on. It's one of the most bought supplements in Europe — you'll find it in every Boots, every dm, every supermarket. Cheap, familiar, almost invisible on the shelf. That familiarity has become a problem for brands trying to differentiate.
Marco: A new clinical trial — that's a controlled human study, not just observational data — found that daily vitamin C supplementation could improve survival rates in people with precancerous blood disorders and early-stage blood cancers. That's a meaningful result. Clinical trials sit much higher in the evidence hierarchy than the population studies this ingredient usually relies on.
Klara: I want to be clear about what this is and what it isn't. This is a specific finding in a specific population — people with precancerous blood conditions. It does not mean vitamin C treats or prevents cancer broadly. Under EU health claims regulation — that's EC 1924/2006, the rulebook for what supplement brands can say on pack and in advertising — you cannot make disease treatment claims. Full stop. Brands that push this finding into general cancer prevention messaging will be in trouble fast.
Marco: Agreed on the compliance risk. But here's what excites me commercially. The longevity and healthy ageing segment is exploding across Europe. This trial gives brands an opportunity to build credible educational content — not label claims, but storytelling. White papers, practitioner briefings, ingredient marketing. There's real space to reposition vitamin C from a commodity into a science-led ingredient with oncology-adjacent credibility.
Klara: Educational content, yes. Health claims on product packaging, absolutely not. The science is promising — but the regulatory gap is real, and brands need to respect it.
Marco: Now let's move to our next story.
Klara: A traditional German milling company is making a €7 million bet on the future of protein.
Klara: Most people don't think about where protein ingredients actually come from before they end up in a supplement or a functional food. But behind every protein bar or shake is an upstream supply chain — the processors and ingredient producers who handle raw materials before brands ever get involved. That layer of the industry is now shifting fast.
Klara: Lebensmittelzeitung published an interview with the leadership of a long-established German milling business — both senior and next-generation family members — announcing a €7 million investment to reposition the company around protein ingredient production. This isn't a startup taking a punt. It's a generational business, retooling its entire operation to serve the growing demand for plant-based and functional protein ingredients from European food and supplement brands.
Marco: From a supply chain perspective, this is a significant signal. When a family-run miller with deep roots in traditional grain processing commits seven figures to pivot toward protein, it tells you the demand is real and sustained. Brands scaling their protein ranges need reliable, differentiated ingredient sources — and right now, supply security is a genuine concern across Europe. More domestic upstream capacity is good news for those brands.
Klara: My interest sits slightly differently. Protein ingredient quality varies enormously — amino acid profile, digestibility, contamination risk. As upstream producers enter this space, the industry needs to hold them to consistent quality standards. More supply is only useful if the ingredient specification is tight.
Marco: That's where I'd push back slightly — actually, where I'd add nuance. Infrastructure investment typically comes before quality refinement. You build capacity first, then you optimise. The certification and quality layer will follow as competition between ingredient suppliers intensifies.
Klara: Let's hope it follows quickly. On to our next story.
Marco: US lawmakers are pushing the FDA to shut down a loophole that's been quietly fuelling a shadow market for unapproved obesity drugs.
Marco: Over the past two years, compounded GLP-1 drugs — that's personalised versions of medicines like semaglutide, made by specialist pharmacies — became a massive grey market in the wellness space. Regulators on both sides of the Atlantic started tightening the rules. But now the problem has moved upstream. Investigational drugs — molecules still in clinical trials, not yet approved for anyone — are being imported and sold informally, particularly in biohacking and longevity communities.
Marco: A bipartisan group of US lawmakers has formally asked the FDA to close a specific importation loophole being exploited to bring in unapproved versions of retatrutide — an investigational obesity drug currently in Eli Lilly's pipeline. It hasn't been approved anywhere. It's still in trials. And yet it's circulating in wellness channels, often marketed as a peptide product.
Klara: This is where the science and safety picture gets genuinely alarming. Investigational drugs haven't completed the safety testing that approved medicines go through. You simply don't know what you're putting into someone's body. In Europe, the EMA — the European Medicines Agency — governs this space, and unapproved drug substances marketed as supplements would almost certainly fall foul of both medicines law and novel food regulation. The exposure for any brand adjacent to these ingredients is serious.
Marco: Commercially, I'd actually disagree with framing this purely as a warning. Brands in the legitimate weight management and longevity supplement space have an opportunity here. When grey-market products get scrutinised, compliant brands gain credibility by contrast. The smart move is a clean ingredient audit now, before European regulators start asking the same questions the FDA is being pushed to ask.
Klara: Audit first. The regulatory tide is moving, and it moves fast.
Marco: Next story — our final one today.
Klara: A biotech startup just launched a lab-grown cocoa ingredient aimed squarely at food and supplement manufacturers.
Klara: Cacao has built genuine functional credibility over the past few years. Flavanols — the active compounds in cocoa — have attracted serious research interest around cognitive health, mood, and cardiovascular support. Brands have been leaning into dark chocolate and cacao as ingredient stories, not just flavour. But the raw cocoa supply chain is under real strain — climate pressure in West Africa, geopolitical instability, price volatility. That combination creates a meaningful problem for brands building product ranges around this ingredient.
Klara: Galy, a US biotech, has launched WunderHaus — a cell-cultured cocoa ingredient sold directly to professional food and supplement manufacturers through B2B channels. Cell-cultured means the cocoa is grown from plant cells in a controlled laboratory environment rather than harvested from cacao trees. The pitch is sustainability and supply security, both of which resonate strongly with European buyers right now.
Klara: My first question is whether the health claim science transfers. EFSA-authorised health claims for cocoa flavanols — the ones legally usable on pack in Europe — are tied to specific compounds at specific concentrations. If cell-cultured cocoa produces a different flavanol profile than conventional cocoa, that evidence base may not apply. Brands cannot assume they can carry existing claims across to a new ingredient without verification.
Marco: That's the right caution, but commercially the supply chain angle matters enormously right now. European functional food brands are actively looking for more resilient ingredient sourcing. A domestically scalable cocoa alternative with a strong sustainability story addresses two problems at once — cost unpredictability and ESG pressure from retail buyers.
Klara: The science needs to follow the supply story, not lag behind it. Brands that get the claim validation right early will be well ahead of the curve.
Marco: Today's throughline is clear — legacy ingredients, legacy businesses, and legacy regulators are all being forced to evolve faster than they planned.
Klara: And the brands that will win are the ones pairing genuine clinical evidence with smart compliance — not the ones cutting corners on either.